Advice

following a full submission:

ferric maltol (Feraccru®) is not recommended for use within NHS Scotland.

Indication under review: in adults for the treatment of iron deficiency anaemia (IDA) in patients with inflammatory bowel disease (IBD).

In a pooled analysis of two phase III studies in IBD patients with IDA who had failed previous treatment with oral ferrous products, there was a significantly greater increase in haemoglobin concentrations after 12 weeks of ferric maltol treatment compared with placebo.

The submitting company did not present sufficiently robust clinical and economic analyses to gain acceptance by SMC.

Download detailed advice219KB (PDF)

Download

Medicine details

Medicine name:
ferric maltol (Feraccru)
SMC ID:
1202/16
Indication:
In adults for the treatment of iron deficiency anaemia (IDA) in patients with inflammatory bowel disease (IBD).
Pharmaceutical company
Shield Therapeutics
BNF chapter
Nutrition and blood
Submission type
Full
Status
Not recommended
Date advice published
12 December 2016